Bora Pharmaceuticals Co (保瑞藥業) has acquired six brand product licenses, rights and process technologies in the US for US$38.5 million, and expects them to start contributing to revenue in the fourth quarter of this year, the company said in a filing with the Taiwan Stock Exchange yesterday.
Bora’s board of directors approved the deal with Morristown, New Jersey-based Almatica Pharma Inc, as the Taiwanese firm moves into the brand product market to diversify risks away from generic drugs, the filing said.
The deal would enable Bora to leverage its sales platforms to enter the brand product market, it said.
Photo: CNA
Established in 2008, Almatica —a US subsidiary of Alvogen Group — focuses on the development, acquisition and commercialization of pharmaceutical products. Its product portfolio includes psychiatry, pain management, anti-infective and cardiovascular treatments, the company’s Web site says.
The six brand products are Zestril, Tenormin and Tenoretic for cardiovascular treatment, and Forfivo XL, Naprelan and Fluoxetine HCL for treating central nervous system issues, Bora said.
Sales of the six drugs in the US totaled about US$220 million last year, the company said, citing data from life sciences researcher Iqvia Institute.
As the deal was conducted through Bora’s subsidiary TWi Pharmaceuticals Inc (安成藥), it would greatly bolster the generic-drug unit’s product portfolio in the US market, while reducing its concentration on generic drugs, Bora chairman Bobby Sheng (盛保熙) told an investors’ conference in Taipei yesterday.
After TWi completes its takeover of the six products’ licenses and rights, it can deploy Bora group’s contract manufacturing and development expertise for mass production, which would not only increase TWi’s profit, but also boost the parent company’s global contract manufacturing business, Sheng said.
Bora’s second-quarter net profit surged 192 percent to NT$700.83 million (US$21.92 million) from NT$239.99 million in the same period last year. That translated into earnings per share (EPS) of NT$8.95, compared with NT$3.2 a year earlier.
EPS in the first half of the year was NT$22.54, up from NT$5.57 a year earlier, while gross margin improved to 46.09 percent, from 37.12 percent, it said.
With cumulative revenue in the first half of the year jumping 220.5 percent year-on-year to NT$7.92 billion and a better business outlook, the company yesterday raised its annual revenue growth forecast to between 30 and 35 percent, from its previous estimate of 20 to 30 percent.
It also raised its gross margin forecast to between 45 and 50 percent, from its earlier projection of 45 percent.
CAUTIOUS RECOVERY: While the manufacturing sector returned to growth amid the US-China trade truce, firms remain wary as uncertainty clouds the outlook, the CIER said The local manufacturing sector returned to expansion last month, as the official purchasing managers’ index (PMI) rose 2.1 points to 51.0, driven by a temporary easing in US-China trade tensions, the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. The PMI gauges the health of the manufacturing industry, with readings above 50 indicating expansion and those below 50 signaling contraction. “Firms are not as pessimistic as they were in April, but they remain far from optimistic,” CIER president Lien Hsien-ming (連賢明) said at a news conference. The full impact of US tariff decisions is unlikely to become clear until later this month
GROWING CONCERN: Some senior Trump administration officials opposed the UAE expansion over fears that another TSMC project could jeopardize its US investment Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is evaluating building an advanced production facility in the United Arab Emirates (UAE) and has discussed the possibility with officials in US President Donald Trump’s administration, people familiar with the matter said, in a potentially major bet on the Middle East that would only come to fruition with Washington’s approval. The company has had multiple meetings in the past few months with US Special Envoy to the Middle East Steve Witkoff and officials from MGX, an influential investment vehicle overseen by the UAE president’s brother, the people said. The conversations are a continuation of talks that
CHIP DUTIES: TSMC said it voiced its concerns to Washington about tariffs, telling the US commerce department that it wants ‘fair treatment’ to protect its competitiveness Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday reiterated robust business prospects for this year as strong artificial intelligence (AI) chip demand from Nvidia Corp and other customers would absorb the impacts of US tariffs. “The impact of tariffs would be indirect, as the custom tax is the importers’ responsibility, not the exporters,” TSMC chairman and chief executive officer C.C. Wei (魏哲家) said at the chipmaker’s annual shareholders’ meeting in Hsinchu City. TSMC’s business could be affected if people become reluctant to buy electronics due to inflated prices, Wei said. In addition, the chipmaker has voiced its concern to the US Department of Commerce
STILL LOADED: Last year’s richest person, Quanta Computer Inc chairman Barry Lam, dropped to second place despite an 8 percent increase in his wealth to US$12.6 billion Staff writer, with CNA Daniel Tsai (蔡明忠) and Richard Tsai (蔡明興), the brothers who run Fubon Group (富邦集團), topped the Forbes list of Taiwan’s 50 richest people this year, released on Wednesday in New York. The magazine said that a stronger New Taiwan dollar pushed the combined wealth of Taiwan’s 50 richest people up 13 percent, from US$174 billion to US$197 billion, with 36 of the people on the list seeing their wealth increase. That came as Taiwan’s economy grew 4.6 percent last year, its fastest pace in three years, driven by the strong performance of the semiconductor industry, the magazine said. The Tsai